CSRNP3

Summary

CSRNP3 (cysteine and serine rich nuclear protein 3, HGNC:30729) is a protein-coding gene on chromosome 2q24.3, encoding Cysteine/serine-rich nuclear protein 3 (Q8WYN3). Binds to the consensus sequence 5’-AGAGTG-3’ and has transcriptional activator activity.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and sequence-specific DNA binding activity. Predicted to be involved in positive regulation of apoptotic process and positive regulation of transcription by RNA polymerase II. Predicted to be located in chromatin. Predicted to be active in nucleus.

Source: NCBI Gene 80034 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 104 total — 11 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001172173

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30729
Approved symbol	CSRNP3
Name	cysteine and serine rich nuclear protein 3
Location	2q24.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ32093, TAIP-2, PPP1R73
Ensembl gene	ENSG00000178662
Ensembl biotype	protein_coding
OMIM	620405
Entrez	80034

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 11 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000314499, ENST00000342316, ENST00000409420, ENST00000409664, ENST00000421875, ENST00000464503, ENST00000651982, ENST00000871763, ENST00000871764, ENST00000871765, ENST00000871766, ENST00000871767

RefSeq mRNA: 2 — MANE Select: NM_001172173 NM_001172173, NM_024969

CCDS: CCDS2225

Canonical transcript exons

ENST00000651982 — 7 exons

Exon	Start	End
ENSE00001578368	165469698	165469740
ENSE00001628995	165517873	165517961
ENSE00001774342	165494759	165494928
ENSE00003889947	165657761	165658020
ENSE00003894547	165676312	165676608
ENSE00003894986	165678701	165689407
ENSE00003895475	165595043	165595213

Expression profiles

Bgee: expression breadth ubiquitous, 226 present calls, max score 98.84.

FANTOM5 (CAGE): breadth broad, TPM avg 8.3927 / max 1263.1181, expressed in 663 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
23427	6.7776	649
23428	0.8433	166
23429	0.4759	115
23431	0.1738	109
23430	0.1221	61

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	98.84	gold quality
middle temporal gyrus	UBERON:0002771	97.42	gold quality
entorhinal cortex	UBERON:0002728	97.09	gold quality
postcentral gyrus	UBERON:0002581	97.08	gold quality
parietal lobe	UBERON:0001872	97.05	gold quality
endothelial cell	CL:0000115	96.18	gold quality
cortical plate	UBERON:0005343	95.53	gold quality
substantia nigra pars compacta	UBERON:0001965	94.88	gold quality
superior frontal gyrus	UBERON:0002661	94.77	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.33	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.66	gold quality
lateral globus pallidus	UBERON:0002476	93.45	gold quality
pigmented layer of retina	UBERON:0001782	93.10	gold quality
superior vestibular nucleus	UBERON:0007227	92.01	gold quality
ventral tegmental area	UBERON:0002691	91.24	gold quality
occipital lobe	UBERON:0002021	90.71	gold quality
primary visual cortex	UBERON:0002436	90.45	gold quality
Brodmann (1909) area 46	UBERON:0006483	88.49	gold quality
cerebellar vermis	UBERON:0004720	87.07	gold quality
adult organism	UBERON:0007023	86.93	gold quality
medulla oblongata	UBERON:0001896	85.79	gold quality
seminal vesicle	UBERON:0000998	84.79	gold quality
tibia	UBERON:0000979	84.75	gold quality
mucosa of paranasal sinus	UBERON:0005030	84.69	gold quality
ganglionic eminence	UBERON:0004023	84.23	gold quality
corpus callosum	UBERON:0002336	84.07	gold quality
temporal lobe	UBERON:0001871	83.42	gold quality
cerebral cortex	UBERON:0000956	83.16	gold quality
dorsal plus ventral thalamus	UBERON:0001897	82.93	gold quality
prefrontal cortex	UBERON:0000451	82.61	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.47
E-MTAB-6058	no	592.40
E-GEOD-99795	no	21.19

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1

miRNA regulators (miRDB)

345 targeting CSRNP3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-513B-5P	99.99	69.96	2150

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	CSRNP3	ENSDARG00000079741
mus_musculus	Csrnp3	ENSMUSG00000044647
rattus_norvegicus	Csrnp3	ENSRNOG00000005359
drosophila_melanogaster	Axud1	FBGN0261647
caenorhabditis_elegans	C41D11.3	WBGENE00016562

Paralogs (2): CSRNP2 (ENSG00000110925), CSRNP1 (ENSG00000144655)

Protein

Protein identifiers

Cysteine/serine-rich nuclear protein 3 — Q8WYN3 (reviewed: Q8WYN3)

Alternative names: Protein FAM130A2, TGF-beta-induced apoptosis protein 2

All UniProt accessions (4): B8ZZD9, E7EN18, Q8WYN3, J3KQ49

UniProt curated annotations — full annotation on UniProt →

Function. Binds to the consensus sequence 5’-AGAGTG-3’ and has transcriptional activator activity. Plays a role in apoptosis.

Subcellular location. Nucleus.

Similarity. Belongs to the AXUD1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8WYN3-1	1	yes
Q8WYN3-2	2

RefSeq proteins (2): NP_001165644, NP_079245 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR023260	Cys/Ser-rich_nuc_prot	Family
IPR031972	CSRNP_N	Domain

Pfam: PF16019

UniProt features (11 total): compositionally biased region 5, region of interest 2, splice variant 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WYN3-F1	60.42	0.26

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 219 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, GCACCTT_MIR18A_MIR18B, RNGTGGGC_UNKNOWN, HNF3ALPHA_Q6, XU_GH1_AUTOCRINE_TARGETS_UP, TGCACTT_MIR519C_MIR519B_MIR519A, TGACCTY_ERR1_Q2, FOXO1_01, CAGGTCC_MIR492, AAAYRNCTG_UNKNOWN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, CAGCTG_AP4_Q5, GGCNKCCATNK_UNKNOWN, COUP_01, BRN2_01

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), apoptotic process (GO:0006915), positive regulation of apoptotic process (GO:0043065), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (5): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA-binding transcription factor activity (GO:0003700), sequence-specific DNA binding (GO:0043565), DNA binding (GO:0003677)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
positive regulation of DNA-templated transcription	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
DNA binding	1
nucleic acid binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

480 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CSRNP3	ENPP5	Q9UJA9	478
CSRNP3	GPD2	P43304	458
CSRNP3	SCGB3A2	Q96PL1	454
CSRNP3	LMNTD1	Q8N9Z9	453
CSRNP3	PDGFD	Q9GZP0	401
CSRNP3	DENND1A	Q8TEH3	386
CSRNP3	BSDC1	Q9NW68	385
CSRNP3	KANSL1L	A0AUZ9	379
CSRNP3	SPHKAP	Q2M3C7	377
CSRNP3	SLC38A11	Q08AI6	374
CSRNP3	NR6A1	Q15406	373
CSRNP3	SCN3A	Q9NY46	366
CSRNP3	PPP2R3B	Q9Y5P8	366
CSRNP3	ANOS1	P23352	360
CSRNP3	HRC	P23327	355

IntAct

3 interactions, top by confidence:

A	B	Type	Score
PPP1CA	CSRNP3	psi-mi:“MI:0407”(direct interaction)	0.440
JUP	CSRNP3	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (3): CSRNP3 (Affinity Capture-MS), CSRNP3 (Affinity Capture-MS), CSRNP3 (Affinity Capture-Western)

ESM2 similar proteins: A2X0Q0, B0S6S9, M0R5D6, O13606, O60291, O60381, P0C2N5, P16075, P32314, P59055, Q0P4S0, Q1LXZ9, Q28J76, Q2KJ34, Q2PFD7, Q3TEL6, Q3U8K7, Q4FZB7, Q5R7I3, Q5SPL2, Q5SW75, Q5XI67, Q5XIQ4, Q60DG4, Q61IS6, Q62661, Q66H65, Q6AXJ7, Q6DDX3, Q6GP60, Q6KAQ7, Q6NRK3, Q6PEV8, Q6YXZ4, Q76I76, Q865B7, Q8BGQ2, Q8BIA3, Q8CDG5, Q8IYH5

Diamond homologs: P59054, P59055, Q5R638, Q8BGQ2, Q8WYN3, Q96S65, Q9H175

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	11
Likely pathogenic	2
Uncertain significance	84
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (13)

Variant ID	HGVS	Classification
1526930	GRCh37/hg19 2q24.3(chr2:165794558-166633875)	Pathogenic
153359	GRCh38/hg38 2q24.3(chr2:165238425-166114982)x1	Pathogenic
155321	GRCh38/hg38 2q24.3(chr2:165222998-166664612)x1	Pathogenic
253660	GRCh37/hg19 2q24.3(chr2:166094617-166931348)x3	Pathogenic
442768	GRCh37/hg19 2q24.3(chr2:166032047-168283204)x1	Pathogenic
530654	NC_000002.12:g.(?165090130)(166228992_?)del	Pathogenic
635920	Single allele	Pathogenic
813715	GRCh37/hg19 2q24.3(chr2:166340583-166904859)	Pathogenic
830392	NC_000002.12:g.(?165090130)(166204484_?)del	Pathogenic
984751	GRCh37/hg19 2q24.3(chr2:166060478-166349787)x1	Pathogenic
997058	GRCh37/hg19 2q24.3(chr2:165903672-166666206)	Pathogenic
153729	GRCh38/hg38 2q24.3(chr2:164941760-165764726)x3	Likely pathogenic
444847	GRCh37/hg19 2q24.3(chr2:166221754-166646820)x1	Likely pathogenic

SpliceAI

2070 predictions. Top by Δscore:

Variant	Effect	Δscore
2:165494924:TACCA:T	donor_gain	1.0000
2:165494926:CCA:C	donor_gain	1.0000
2:165494927:CA:C	donor_gain	1.0000
2:165494928:AG:A	donor_loss	1.0000
2:165494929:G:GG	donor_gain	1.0000
2:165494930:TGAG:T	donor_loss	1.0000
2:165494931:GAGTA:G	donor_loss	1.0000
2:165494932:AG:A	donor_loss	1.0000
2:165517871:A:G	acceptor_gain	1.0000
2:165517957:TCAAG:T	donor_loss	1.0000
2:165517958:CAAGG:C	donor_loss	1.0000
2:165517959:AAGGT:A	donor_loss	1.0000
2:165517960:AG:A	donor_loss	1.0000
2:165517961:GGT:G	donor_loss	1.0000
2:165517962:GTT:G	donor_loss	1.0000
2:165517963:T:A	donor_loss	1.0000
2:165595035:T:A	acceptor_gain	1.0000
2:165595040:CAGG:C	acceptor_loss	1.0000
2:165595041:AGG:A	acceptor_loss	1.0000
2:165595042:GGT:G	acceptor_gain	1.0000
2:165595042:GGTA:G	acceptor_gain	1.0000
2:165595042:GGTAC:G	acceptor_gain	1.0000
2:165595209:TACCC:T	donor_gain	1.0000
2:165595211:CCC:C	donor_gain	1.0000
2:165595212:CC:C	donor_gain	1.0000
2:165595213:CG:C	donor_loss	1.0000
2:165595214:G:GG	donor_gain	1.0000
2:165595214:GT:G	donor_loss	1.0000
2:165595215:T:TG	donor_loss	1.0000
2:165595216:GAG:G	donor_loss	1.0000

AlphaMissense

3889 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:165657811:T:C	F67L	1.000
2:165657812:T:C	F67S	1.000
2:165657812:T:G	F67C	1.000
2:165657813:T:A	F67L	1.000
2:165657813:T:G	F67L	1.000
2:165657821:T:A	V70D	1.000
2:165657827:T:A	V72E	1.000
2:165657829:T:G	Y73D	1.000
2:165657835:T:A	F75I	1.000
2:165657835:T:C	F75L	1.000
2:165657835:T:G	F75V	1.000
2:165657836:T:C	F75S	1.000
2:165657836:T:G	F75C	1.000
2:165657837:C:A	F75L	1.000
2:165657837:C:G	F75L	1.000
2:165657841:A:G	R77G	1.000
2:165657842:G:C	R77T	1.000
2:165657842:G:T	R77M	1.000
2:165657843:G:C	R77S	1.000
2:165657843:G:T	R77S	1.000
2:165657849:A:C	Q79H	1.000
2:165657849:A:T	Q79H	1.000
2:165657850:G:C	G80R	1.000
2:165657850:G:T	G80C	1.000
2:165657851:G:A	G80D	1.000
2:165657851:G:T	G80V	1.000
2:165657853:T:A	F81I	1.000
2:165657853:T:C	F81L	1.000
2:165657853:T:G	F81V	1.000
2:165657854:T:C	F81S	1.000

dbSNP variants (sampled 300 via entrez): RS1000001242 (2:165580072 G>A), RS1000024753 (2:165594957 G>A,C,T), RS1000031155 (2:165517176 T>A,G), RS1000033356 (2:165641787 A>C), RS1000044897 (2:165510940 A>G), RS1000066482 (2:165547252 A>G), RS1000070540 (2:165501098 T>C), RS1000071115 (2:165654981 A>C), RS1000073280 (2:165530199 T>C), RS1000080799 (2:165494581 T>C), RS1000092822 (2:165593616 G>A,T), RS1000119650 (2:165667224 C>G,T), RS1000134727 (2:165494243 G>A), RS1000153067 (2:165687394 G>A), RS1000163494 (2:165621374 A>G)

Disease associations

OMIM: gene MIM:620405 | disease phenotypes: MIM:613863, MIM:201300, MIM:217990

GenCC curated gene-disease

Mondo (7): developmental and epileptic encephalopathy (MONDO:0100620), generalized epilepsy with febrile seizures plus, type 7 (MONDO:0013470), neuropathy, hereditary sensory and autonomic, type 2A (MONDO:0024309), epilepsy (MONDO:0005027), microcephaly (MONDO:0001149), complex neurodevelopmental disorder (MONDO:0100038), corpus callosum, agenesis of (MONDO:0009022)

Orphanet (5): Genetic epilepsy with febrile seizure plus (Orphanet:36387), Hereditary sensory and autonomic neuropathy type 2 (Orphanet:970), Non-specific syndromic intellectual disability (Orphanet:528084), Lateral facial cleft (Orphanet:141269), Isolated corpus callosum agenesis (Orphanet:200)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002403_1	Longevity (85 years and older)	9.000000e-06
GCST003209_9	Colorectal or endometrial cancer	4.000000e-06
GCST005795_16	Femoral neck bone mineral density	6.000000e-16
GCST005796_5	Lumbar spine bone mineral density	2.000000e-11
GCST008103_11	Bipolar disorder	2.000000e-09
GCST010002_403	Refractive error	1.000000e-11
GCST012597_7	Attention deficit hyperactivity disorder	1.000000e-06
GCST90011900_172	Serum alkaline phosphatase levels	3.000000e-12

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004230	endometrial neoplasm
EFO:0007785	femoral neck bone mineral density
EFO:0007701	spine bone mineral density
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D061085	Agenesis of Corpus Callosum	C10.500.034; C16.131.666.034; C23.300.008
D004827	Epilepsy	C10.228.140.490
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
C567827	Generalized Epilepsy With Febrile Seizures Plus, 7 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs7588295	Toxicity	3	Bisphosphonates	Osteonecrosis

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs7588295	CSRNP3	3	0.00	1	Bisphosphonates

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases methylation, affects expression, decreases expression	4
methylmercuric chloride	decreases expression, affects cotreatment	3
bisphenol A	affects cotreatment, increases methylation, increases expression	2
trichostatin A	affects cotreatment, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases methylation	1
arsenite	affects binding, decreases reaction	1
hydroquinone	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
2,2’,4,4’,5-brominated diphenyl ether	decreases expression	1
torcetrapib	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
NSC 689534	affects binding, decreases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Panobinostat	affects cotreatment, decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Copper	affects binding, decreases expression	1
Doxorubicin	decreases expression	1
Lead	affects expression	1
Nickel	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1
1-Methyl-4-phenylpyridinium	decreases expression	1
Cyclosporine	decreases expression	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00004637	PHASE4	COMPLETED	Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
NCT00043914	PHASE4	COMPLETED	Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00132223	PHASE4	UNKNOWN	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients
NCT00133081	PHASE4	UNKNOWN	Study to Improve the Treatment of Epilepsy (SITE)
NCT00137709	PHASE4	UNKNOWN	Hormone Profiles in Adults With Newly Diagnosed Epilepsy
NCT00154076	PHASE4	COMPLETED	A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
NCT00165828	PHASE4	TERMINATED	Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
NCT00181116	PHASE4	COMPLETED	Levetiracetam for Benign Rolandic Epilepsy
NCT00207935	PHASE4	COMPLETED	Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
NCT00215592	PHASE4	COMPLETED	Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
NCT00266604	PHASE4	COMPLETED	A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
NCT00288639	PHASE4	COMPLETED	Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00312676	PHASE4	UNKNOWN	Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote
NCT00323947	PHASE4	COMPLETED	Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
NCT00385411	PHASE4	COMPLETED	Study of Valproate in Young Patients Suffering From Epilepsy
NCT00522418	PHASE4	TERMINATED	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
NCT00537940	PHASE4	COMPLETED	Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
NCT00552526	PHASE4	UNKNOWN	Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
NCT00564915	PHASE4	COMPLETED	RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
NCT00571155	PHASE4	COMPLETED	Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery
NCT00572195	PHASE4	COMPLETED	RNS® System LTT Study
NCT00610532	PHASE4	TERMINATED	Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
NCT00630357	PHASE4	COMPLETED	Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
NCT00630630	PHASE4	COMPLETED	Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
NCT00630968	PHASE4	COMPLETED	S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00631150	PHASE4	COMPLETED	A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00659958	PHASE4	COMPLETED	ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
NCT00713622	PHASE4	COMPLETED	Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
NCT00807989	PHASE4	COMPLETED	The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
NCT00832884	PHASE4	COMPLETED	The Safety of Intravenous Lacosamide
NCT00869622	PHASE4	COMPLETED	Antiepileptic Drugs and Osteoporotic Prevention Trial
NCT00896987	PHASE4	COMPLETED	Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies
NCT00952081	PHASE4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT01118455	PHASE4	TERMINATED	Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
NCT01127165	PHASE4	COMPLETED	Low and High Dose Zonisamide in Children as Monotherapy
NCT01127256	PHASE4	COMPLETED	Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation
NCT01140867	PHASE4	COMPLETED	Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
NCT01175954	PHASE4	COMPLETED	Cognitive and Behavioral Effects of Lacosamide
NCT01229735	PHASE4	COMPLETED	Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
NCT01244724	PHASE4	TERMINATED	Lexapro for Major Depression in Patients With Epilepsy